XERS News and Press, Xeris Pharmaceuticals Inc. From 02/09/22

Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a ...

Recorlev ® (levoketoconazole) now exclusively available through PANTHERx Rare Specialty Pharmacy To increase patient access to Recorlev, the Company has established Xeris CareConnection™, a comprehensive support program, which includes $0 co-pay for commerciall...

Preliminary 2021 full-year pro forma net sales at high-end of $76-80 million guidance, representing approximately 55% growth from 2020 Year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million 20+ million Medicaid lives in IL, TN, ...

PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome PR Newswire PITTSBURGH , Jan. 13, 2022 /PRNewswire/ -- PANTHERx Rare ...

Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Biopharma, wi...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2,...

Shares of Xeris Biopharma (NASDAQ: XERS) , a small-cap biopharmaceutical company, are on the move following good news from the Food and Drug Administration (FDA). Investors excited about the company's latest new drug approval drove the stock 27.7% higher as of 12:07 p.m. ET on Frida...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xeris Biopharma (NASDAQ: XERS ) stock is rallying after the drug maker announced that its Recorlev drug had been approved by the U.S. Food and Drug Administration for certain patients with Cushing’s syndrome....

FDA approval supported by positive results from the pivotal Phase 3 SONICS and LOGICS studies demonstrating Recorlev to be a safe and effective therapeutic option in the treatment of Cushing's syndrome FDA decision follows successful completion of acquisition of Strongbridge B...

Xeris Pharmaceuticals acquired Strongbridge Biopharma in a stock swap and contingent value rights transaction. The combined company is now called Xeris Biopharma Holdings. Recorlev is ready for approval in Endogenous Cushing’s Syndrome. The FDA set the PDUFA date for January 1s...